This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 1998;279:984.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has issued new rules that for the first time require sponsors of drug, device, or biologic marketing applications to disclose whether clinical investigators performing clinical studies on their products have financial interests that could affect the reliability of submissions for approval. The agency believes it is important to public health to ensure, as much as possible, that the safety and efficacy data submitted to the agency in support of marketing applications are free of the effects of any bias that may result from such financial interests. Public comments in response to the rule when first issued as a proposal indicate that potentially problematic financial arrangements occur only occasionally, although perhaps more often within small biotechnology and medical device firms.

The new rule identifies types of investigator financial arrangements that should be disclosed, including compensation whose value could be affected by the study outcome; proprietary interest, such as a . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?